Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 6263

Sort by

Sort Order Select

Journal Articles

To start and stop or just keep going?

John G. Gribben

Blood (2021) 138 (10): 819–820.

https://doi.org/10.1182/blood.2021012675

Published: 2021

Journal Articles

Notch signaling promotes disease initiation and progression in murine chronic lymphocytic leukemia

Delphine Tardivon, Mateusz Antoszewski, Nadine Zangger, Marianne Nkosi, Jessica Sordet-Dessimoz, Rudi Hendriks, Ute Koch, Freddy Radtke

Blood (2021) 137 (22): 3079–3092.

https://doi.org/10.1182/blood.2020006701

Published: 2021

Includes: Supplemental data

Journal Articles

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

Blood (2021) 137 (22): 3093–3104.

https://doi.org/10.1182/blood.2020007626

Published: 2021

Includes: Supplemental data

Journal Articles

Progression signature underlies clonal evolution and dissemination of multiple myeloma

Yu Jia Shen, Yuji Mishima, Jiantao Shi, Romanos Sklavenitis-Pistofidis, Robert A. Redd, Michele Moschetta, Salomon Manier, Aldo M. Roccaro, Antonio Sacco, Yu-Tzu Tai, Francois Mercier, Yawara Kawano, Nang Kham Su, Brianna Berrios, John G. Doench, David E. Root, Franziska Michor, David T. Scadden, Irene M. Ghobrial

Blood (2021) 137 (17): 2360–2372.

https://doi.org/10.1182/blood.2020005885

Published: 2021

Includes: Supplemental data

Journal Articles

Preleukemic and leukemic evolution at the stem cell level

Jacob Stauber, John M. Greally, Ulrich Steidl

Blood (2021) 137 (8): 1013–1018.

https://doi.org/10.1182/blood.2019004397

Published: 2021

Journal Articles

Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria

Lova Sun, Daria V. Babushok

Blood (2020) 136 (1): 36–49.

https://doi.org/10.1182/blood.2019000940

Published: 2020

Journal Articles

Genetics of progression from MDS to secondary leukemia

Andrew J. Menssen, Matthew J. Walter

Blood (2020) 136 (1): 50–60.

https://doi.org/10.1182/blood.2019000942

Published: 2020

Journal Articles

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia

Blood (2020) 135 (26): 2337–2353.

https://doi.org/10.1182/blood.2020004834

Published: 2020

Includes: Supplemental data

Journal Articles

CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression

Blood (2020) 135 (15): 1244–1254.

https://doi.org/10.1182/blood.2019003179

Published: 2020

Includes: Supplemental data

Journal Articles

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

Blood (2020) 135 (6): 411–428.

https://doi.org/10.1182/blood.2019001262

Published: 2020

Includes: Supplemental data

Journal Articles

B-cell–specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion

Daniela Asslaber, Yuan Qi, Nicole Maeding, Markus Steiner, Ursula Denk, Jan Philip Höpner, Tanja Nicole Hartmann, Nadja Zaborsky, Richard Greil, Alexander Egle

Blood (2019) 134 (20): 1717–1729.

https://doi.org/10.1182/blood.2019000973

Published: 2019

Includes: Supplemental data

Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Blood (2019) 134 (Supplement_1): 831.

https://doi.org/10.1182/blood-2019-126065

Published: 2019

Journal Articles

Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL)

Geffen Kleinstern, PhD, Daniel R O'Brien, Brian Kabat, B.S., Kari G Rabe, Aaron D. Norman, Huihuang Yan, PhD, Celine M. Vachon, PhD, Shulan Tian, MS, PhD, Timothy G. Call, MD, Sameer A. Parikh, MD, Jose F. Leis, MD PhD, Wei Ding, MD PhD, James R. Cerhan, MD PhD, Neil E. Kay, MD, Esteban Braggio, PhD, Susan L. Slager, PhD

Blood (2019) 134 (Supplement_1): 852.

https://doi.org/10.1182/blood-2019-124346

Published: 2019

Journal Articles

Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival

Blood (2019) 134 (Supplement_1): 855.

https://doi.org/10.1182/blood-2019-126674

Published: 2019

Journal Articles

ATM Germline Variant Increases the Risk of MPN Progression

Theodoros Karantanos, MD PhD, Shruti Chaturvedi, MBBS, MS, Christopher D Gocke, MD, Donna Marie Williams, PhD, Alison R. Moliterno, MD, Evan M Braunstein, MD PhD

Blood (2019) 134 (Supplement_1): 835.

https://doi.org/10.1182/blood-2019-125362

Published: 2019

Journal Articles

Control of HIV-1 Infection By Ferroportin Q248H Mutation

Namita Kumari, PhD, Seyed Mehdi Nouraie, PhD MD, Hatajai Lassiter, MS, BS, Asrar Ahmad, PhD, Kathryn Anastos, Jason Lazar, Seble Kassaye, Bradley Aouizerat, Audrey French, Stephen Gange, Adaora Adimora, Neale Weitzmann, Margaret Fischl, Mirjam-Colette Kempf, Sergei Nekhai, PhD

Blood (2019) 134 (Supplement_1): 953.

https://doi.org/10.1182/blood-2019-128685

Published: 2019

Journal Articles

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Blood (2019) 134 (Supplement_1): 767.

https://doi.org/10.1182/blood-2019-124177

Published: 2019

Journal Articles

Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study

Amer M. Zeidan, MBBS, MHS, James Cavenagh, Maria Teresa Voso, David Taussig, Mar Tormo, Isaac Boss, Wilbert B. Copeland, Vanessa E. Gray, Alessandro Previtali, Tim O'Connor, Shelonitda Rose, CL Beach, Lewis R. Silverman

Blood (2019) 134 (Supplement_1): 829.

https://doi.org/10.1182/blood-2019-122896

Published: 2019

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

Karl M. Kilgore, PhD, Iman Mohammadi, PhD, Amy Schroeder, BPharm, Christie Teigland, PhD, Anna Purdum, PharmD,MS, Gunjan L. Shah, MD

Blood (2019) 134 (Supplement_1): 793.

https://doi.org/10.1182/blood-2019-124364

Published: 2019

NARROW

To start and stop or just keep going?

Notch signaling promotes disease initiation and progression in murine chronic lymphocytic leukemia

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

Progression signature underlies clonal evolution and dissemination of multiple myeloma

Preleukemic and leukemic evolution at the stem cell level

Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria

Genetics of progression from MDS to secondary leukemia

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia

CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

B-cell–specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL)

Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival

ATM Germline Variant Increases the Risk of MPN Progression

Control of HIV-1 Infection By Ferroportin Q248H Mutation

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only